Company / Net Income
CUMBERLAND PHARMACEUTICALS INC Net Income History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Net Income
$1.3M
FY2025
5-year range
-$6.3M / $1.3M
FY2021-FY2025
Trend
+120.0%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Net Income returned to growth in FY2025 after 2 years of decline, reaching $1M.
Based on SEC 10-K filings.
$1M in FY2025.
Improved from -$6M to $1M over the past 2 years.
Net Income over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- In FY2025, net income increased 120.0% year-over-year.
- Peak net income was recorded in FY2016.
- Lowest net income in the period was in FY2024.
Company context
Key Data Points
- Altman Z-Score 0.11 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Net IncomeValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $1.3M | +120.0% |
| FY2024 | -$6.3M | -12.7% |
| FY2023 | -$5.6M | -58.8% |
| FY2022 | -$3.5M | +0.9% |
| FY2021 | -$3.5M | -5.9% |
| FY2020 | -$3.3M | +5.6% |
| FY2019 | -$3.5M | -274.5% |
| FY2018 | -$944.7K | -229.2% |
| FY2017 | $731.4K | -69.8% |
| FY2016 | $2.4M | +215.2% |
As of FY2025 · SEC 10-K · Updated Jun 24, 2026